Global Radiodermatitis Market grows with rising prevalence of cancer


Posted August 21, 2017 by priyankadkulkarni

Global Radiodermatitis Market was valued at US$299.6 mn in 2015 and is projected to expand at a CAGR of 3.9% from 2016 to 2024 to reach US$421.5 mn by 2024.

 
Global Radiodermatitis Market: Snapshot

The global radiodermatitis market has been witnessing a significant progress over the last few years on the grounds of the rising prevalence of cancer and the growing uptake of radiation therapy for its treatment. Thanks to the increasing focus on product innovations and advancements in existing products, the market is also showing high potential for future growth.

Over the coming years, the unmet medical needs of consumers in emerging regions is expected to open a plethora of growth opportunities for market players, leading to a substantial rise in this market. Expanding at a CAGR of 3.90% over the period from 2016 to 2024, the market, which stood at US$299.6 mn in 2015, is anticipated to increase to US$421.5 mn by the end of the forecast period.

Obtain Report Details @ http://www.transparencymarketresearch.com/pressrelease/radiodermatitis-market.htm

Asia Pacific to Retain Leadership in Global Radiodermatitis Market

Spread across Asia Pacific, the Middle East and Africa, North America, Latin America, and Europe, the market for radiodermatitis boasts of a robust presence across the world. Asia Pacific, among all, has been leading the global radiodermatitis market, thanks to a higher percentage of patients eligible for radiotherapy. The increasing pool of cancer patients is expected to drive the Asia Pacific radiodermatitis market further, ensuring its dominance over the next few years. Since a number of Asian economies, situated in the tropical region, have humid weather conditions, the severity of radiation dermatitis is significantly high in this geographical segment, which is also expected to boost the market for radiodermatitis in Asia Pacific in the near future.

Amongst other regional markets for radiodermatitis, Europe also possesses a considerable share in the global market on account of the increase in research and development activities in life sciences, upswing in academic research in radiation dermatitis, and the escalating number of product launches in this region. The market in North America has been driven by the presence of a large pool of well-established pharmaceutical enterprises, research organizations, and several government institutes, which actively work on developing a standard treatment solution for radiodermatitis.

Latin America and the Middle East and Africa are likely to gain considerably from the increasing attention of multinational companies on them. The large base of the unprivileged population, particularly in the Middle East and central Africa, and the implementation of new policies encouraging the uptake of radiotherapy in these regions are anticipated to boost the radiodermatitis markets in Latin America and the Middle East and Africa.

Topical Agents to Continue Being Most Valued Radiodermatitis Products

Topical, oral medication, and dressings are the main products available in the global market for radiodermatitis. Topical agents witness a higher demand from end users than other radiodermatitis products and are anticipated to continue doing so over the next few years. The ease of availability and cost benefits of topical products have fueled their demand among all strata of consumers, which is likely to reflect positively on their sales in the near future.

Corticosteroid creams, hydrophilic creams, and topical antibiotics are most preferred topical products across the world. Hydrophilic creams report a much higher demand than the other two. Analysts expect this scenario to remain so over the years to come.

Fill the Form to Gain Deeper Insights on this Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2157

Stratpharma AG, Smith & Nephew Plc, Molnlycke Health Care, Intermed Pharmaceuticals, Derma Sciences Inc., ConvaTec Inc., BMG Pharma S.r.l., Acelity LP Inc., and 3M are the key participants in the global Radiodermatitis market.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Transparency Market Research
Country United States
Categories Health , Marketing , News
Tags radiodermatitis market , radiodermatitis market analysis
Last Updated August 21, 2017